<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01723020</url>
  </required_header>
  <id_info>
    <org_study_id>20120106</org_study_id>
    <nct_id>NCT01723020</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma</brief_title>
  <official_title>A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human, open-label, sequential dose escalation and expansion study of AMG 232 in
      subjects with advanced solid tumors or multiple myeloma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is an open-label, dose exploration study evaluating AMG 232 in subjects
      with advanced p53WT solid tumors or multiple myeloma. The study will be conducted in 2 parts:
      Part 1 - Dose Exploration (parts 1a, 1b and 1c) and Part 2 - Dose Expansion. Part 1a is aimed
      at evaluating the safety, tolerability, PK and PD of AMG 232 and determining the MTD of a
      7-day once daily (QD) dosing schedule in subjects with advanced solid tumors using a
      practical continuous reassessment method (CRM). Part 1b will evaluate the safety and
      tolerability of 3-day QD dosing schedule (or alternate dosing schedule based upon emerging
      data) with a particular emphasis on evaluating the tolerability of daily doses equal to or
      higher than the part 1a MTD in subjects with solid tumors or multiple myeloma. Part 1c will
      evaluate the safety and tolerability of 7-day twice daily (BID) dosing schedule with daily
      cumulative doses equal to or higher than the part 1a MTD in subjects with solid tumors. The
      dose expansion part of the study (Part 2) can open once the MTD has been determined in Part
      1a. Part 2, part 1b and part 1c can be explored in parallel. The dose expansion part will
      consist of up to 85 additional subjects with specific tumors harboring MDM2 amplification
      (liposarcoma [LPS], gliobastoma [ GBM ] and all other solid tumors) or potentially harboring
      MDM2 overexpression (ER+ metastatic breast cancer) and a group of subjects with multiple
      myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 27, 2012</start_date>
  <completion_date type="Actual">September 25, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>36 months</time_frame>
    <description>Subject incidence of adverse events, dose limiting toxicities, and clinically significant changes in vital signs, weight, ECGs and clinical laboratory tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response</measure>
    <time_frame>36 months</time_frame>
    <description>Duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, for multiple myeloma using IMWG response criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Advanced Malignancy</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Oncology</condition>
  <condition>Oncology Patients</condition>
  <condition>Tumors</condition>
  <condition>Glioblastoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>AMG 232</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 232 is an anti-cancer agent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 232</intervention_name>
    <description>Given an an oral tablet in escalating doses.</description>
    <arm_group_label>AMG 232</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt; 18 years old

          -  Pathologically documented, definitively diagnosed, advanced solid tumor that is
             refractory to standard treatment, or which no standard therapy is available, or the
             subject refuses standard therapy or multiple myeloma

          -  Willing to undergo pre-dose core needle tumor biopsies or bone marrow aspirate for
             subjects with multiple myeloma.

          -  Ability to take oral medications and willing to record daily adherance to
             investigational product

          -  Adequate hematological, renal, hepatic, and coagulation laboratory assessments

        Exclusion Criteria:

          -  Active brain metastases

          -  For solid tumor-History or presence of hematological malignancies unless curatively
             treated with no evidence of disease for greater than or equal to 5 years

          -  Active infection requiring intravenous (IV) antibiotics

          -  Anti-tumor therapy

          -  Therapeutic or palliative radiation therapy within 30 days of starting treatment

          -  Currently enrolled in another investigational device or drug study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyon CEDEX 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2012</study_first_submitted>
  <study_first_submitted_qc>November 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2012</study_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

